Currently, single node inhibitors (SNIs) of the PI3K/AKT/mTOR pathway alpelisib and inavolisib (targeting PI3Kα) and capivasertib (targeting AKT) have received regulatory approval for breast cancer treatment, while everolimus (mTORC1 inhibitor) is approved for breast cancer and other tumour types. The gene discussed is PIK3CD; the disease is breast carcinoma.